Liposomal Mitoxantrone Shows Early Safety Signal in Phase 2 NMOSD Trial

22 Oct 2026 0 comments

A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.

Source: NeurologyLive Published 22 Oct 2026 Imported 22 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment